Current stock status, expected return dates, and alternative options for accessing tirzepatide.
Last updated: February 12, 2026
Last updated: February 12, 2026
Limited stock available. Availability may vary by pharmacy and location. Contact providers directly to confirm stock.
Most Mounjaro doses showing better availability. FDA removed several doses from shortage list. Some pharmacies still reporting limited stock for certain strengths.
Eli Lilly announced increased production capacity. Gradual improvement in availability across most doses.
Most doses on FDA shortage list. Widespread availability issues at pharmacies nationwide.
While waiting for Mounjaro availability to normalize, compounded tirzepatide offers the same active ingredient at a fraction of the cost.
Compare real-time pricing from 30+ telehealth providers offering compounded tirzepatide.
As of December 2024, Mounjaro supply has significantly improved. While some doses may still have limited availability, most pharmacies now have better stock levels compared to earlier in the year.
Eli Lilly has ramped up production capacity. Supply is expected to continue improving through early 2025, with most doses becoming readily available.
Alternatives include Zepbound (same active ingredient, tirzepatide), compounded tirzepatide from online providers ($297-500/month), or semaglutide-based medications like Wegovy or Ozempic.
Yes, compounded tirzepatide remains widely available from online providers. This is often more affordable than brand-name Mounjaro at $297-500/month vs $1000+/month.
Be notified immediately when Mounjaro availability improves or when better alternatives become available.
